New data from the CONFIDENCE trial demonstrates that combination therapy with finerenone and empagliflozin leads to significantly greater reductions in albuminuria than either agent alone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The breakthrough study was presented today at the 62nd ERA Congress and published in the New England Journal of Medicine.
This article was originally published on MedicalXpress.com
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
Chronic wasting disease (CWD), a devastating prion illness that affects North American cervids like deer and elk, poses a grave threat to their well-being and conservation efforts. Furthermore, it presents a potential risk of human […]
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
© 2025 SimplyWell.ca